Your Health, We Care
Release date: 2024-12-02 14:25:20 Recommended: 95
Olaparib exerts its anti-tumor effect by inhibiting poly ADP ribose polymerase (PARP) and preventing DNA repair of cancer cells. Its applicable patients mainly include those with BRCA gene defects or other DNA repair-related gene mutations. Understanding the pharmacological properties of Olaparib will help adjust the dose in clinical practice and optimize the treatment effect.
PARP is an enzyme that plays a key role in the process of DNA damage repair, mainly including subtypes such as PARP1, PARP2 and PARP3.
PARP participates in normal cell functions such as DNA transcription and DNA repair, and is essential for maintaining cell homeostasis.
Olaparib interferes with a key step in the DNA repair process of tumor cells by inhibiting the activity of PARP enzymes.
After inhibiting PARP, tumor cells cannot effectively repair DNA damage, which in turn triggers cell apoptosis or cell cycle arrest, thereby inhibiting tumor growth.
Olaparib is mainly used to treat diseases such as advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer.
Especially in cancer patients with BRCA mutations, Olaparib showed more significant efficacy.
During the use of Olaparib, patients may experience symptoms such as nausea, vomiting, diarrhea, and anemia.
Especially for anemia symptoms, regular monitoring of blood routine is required for timely detection and treatment.
According to clinical trial data, the recommended initial dose of Olaparib is usually 150 mg twice a day. This dose is suitable for most patients, but not every patient can adapt to this standard dose. Individual differences, comorbidities, liver and kidney function, etc. of patients will affect the metabolism and response of the drug.
The recommended dose for the treatment of ovarian cancer and breast cancer is 300 mg each time, twice a day.
This means a total daily dose of 600 mg.
Olaparib tablets have two specifications: 100 mg and 150 mg.
For a dose of 300 mg each time, you can choose 2 tablets of 150 mg or 3 tablets of 100 mg.
1. Patient age and weight Elderly patients usually have weaker metabolic capacity and may need to reduce the dose. In addition, patients who are underweight may experience more serious side effects when receiving standard doses.
2. Liver and kidney function Patients with impaired liver and kidney function have obstacles in drug metabolism and need to adjust the dose according to the specific situation. According to relevant guidelines, patients with mild liver damage can maintain the standard dose, while patients with moderate to severe liver damage need to reduce the dose.
3. Previous treatment history Patients who have received other chemotherapy or radiotherapy in the past may have physical conditions and residual toxicity that may affect the tolerance of Olaparib, and the dose should be adjusted according to the patient's specific treatment history.
4. Adverse reactions If serious adverse reactions (such as hematological toxicity, liver function damage, etc.) occur during treatment, the patient's condition should be evaluated in time and the dose should be adjusted, and even temporary drug suspension should be considered.
